StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

Equities researchers at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Trading Down 9.8 %

NASDAQ:TRVN opened at $1.75 on Friday. The stock’s 50-day moving average is $3.52 and its 200-day moving average is $6.18. The stock has a market cap of $1.51 million, a P/E ratio of -0.03 and a beta of 1.08. Trevena has a 1-year low of $1.13 and a 1-year high of $19.23.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.25) by $9.02. The business had revenue of $0.33 million during the quarter. As a group, equities analysts forecast that Trevena will post -32.25 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.